REGN250117P455000
- 2.13
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Goldman Sachs Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,185
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $950
Regeneron Pharma Is Maintained at Neutral by Citigroup
Regeneron Pharmaceuticals Analyst Ratings
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $565 to $1,152
Regeneron (REGN) Gets a Buy From Bernstein
Citigroup Cuts Regeneron Pharmaceuticals' Price Target to $795 From $895
Regeneron Pharma Is Maintained at Overweight by Wells Fargo
Regeneron Pharmaceuticals Analyst Ratings
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $900
Oppenheimer Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $950
Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,004
Regeneron Pharmaceuticals Analyst Ratings
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,184
RBC Trims Price Target on Regeneron Pharmaceuticals to $1,184 From $1,215, Keeps Outperform Rating
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,070
CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,152
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $1,190, Keeps Outperform Rating